|
|
Article: Ohmeda expands anesthesia-related offerings with new neuromuscular blocking agent.
- Article from:
- Business Wire
- Article date:
- March 18, 1997
CopyrightCOPYRIGHT 1997 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LIBERTY CORNER, N.J.--(BUSINESS WIRE)--March 18, 1997--The U.S. Food and Drug Administration has approved atracurium besylate injection, a neuromuscular blocking agent, for marketing by Ohmeda, a global market leader in anesthesia and critical care.
Atracurium besylate injection is an intermediate-duration neuromuscular blocking agent used during general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Ohmeda atracurium besylate injection 10 mg/mL in 5- and 10-mL vials is the AP rated bioequivalent to the brand Tracrium(R) and offers 18-month expiration dating (under proper ...